This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Merck’s $2.13B deal with SciBrunch for KRAS G12D inhibitor SPR2015, Abogen’s $7.78B partnership with Novartis for an mRNA T-cell engager, and 3SBio’s ¥1.75B GLP-1 deal with MindRank. Other updates feature AstraZeneca’s $2B investment in Summit, Hengrui’s $2.6B GLP-1/GIP deal with Novo Nordisk, Nhwa’s $500M sleep disorder licensing, Mabwell’s TCE spinout, and clinical milestones from SciBrunch, CSPC, Sciwind, Phrontline, Kailera, and Genmab showing advances in oncology, obesity, and metabolic diseases.
